目的 探讨曲美他嗪联合阿托伐他汀对冠心病患者心功能及炎症因子的影响。方法 选取冠心病患者79例，随机分为对照组（38例）和观察组（41例），2组均给予冠心病常规治疗，对照组加用阿托伐他汀，观察组在对照组基础上加用曲美他嗪，两组患者疗程均为3个月。比较两组患者治疗前后左室后壁厚度（LVPWd），左室射血分数（LVEF）、左室舒张末期内径（LVEDd）、6 min步行距离（6MWD）、C反应蛋白（hsCRP）、白介素-6（IL-6）、血清肿瘤坏死因子-α（TNF-α）水平。结果 治疗后，两组的LVPWd、LVEDd、LVEF、6MWD较治疗前明显改善，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组改善程度显著比对照组好，差异有统计学意义（P<0.05）。治疗后，两组的hsCRP、IL-6、TNF-α均较治疗前显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组降低程度比对照组显著，差异有统计学意义（P<0.05）。结论 曲美他嗪联合阿托伐他汀可有效改善冠心病患者心功能，降低炎症反应。

Objective To investigate the effects of trimetazidine combined with atorvastatin on the cardiac function,inflammatory factors in patients with coronary heart disease (CHD). Methods Choose 79 patients with CHD, who were randomly divided into control group (38 cases) and observation group (41 cases). Both groups were taken routine treatment. The patients in control group were added atorvastatin, while those in observation group were added trimetazidine combined with atorvastatin. All patients were treated for three months. LVPWd, LVEF, LVEDd, 6MWD, hsCRP, IL-6 and TNF-α were compared between control group and observation group before and after treatment. Results After treatment, LVPWd, LVEDd, LVEF, 6MWD of both groups were obviously improved compared with before treatment, and the observation group improved significantly better than the control group (P<0.05). After treatment, hsCRP, IL-6 and TNF-α of both groups were obviously improved compared with before treatment, and the observation group improved significantly better than the control group (P<0.05). Conclusions Trimetazidine combined with atorvastatin can effectively improve heart function, reduce inflammatory reactions in patients with CHD.